🇺🇸·5d agoIndustry
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Publisher
G
Gilead Sciences
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on gilead.com
Leave the platform to read the original full article on the publisher site.
Source: Gilead Sciences
Scope: Industry
Related coverage
More related coverage
AstraZeneca News·1d ago
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic ob...
InflaRx·9h ago
Guggenheim SMID Cap Biotech Conference
InflaRx·9h ago
Piper Sandler 36th Annual Healthcare Conference
InflaRx·9h ago